Actively Recruiting

Age: 18Years - 75Years
FEMALE
NCT06784921

To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.

Led by Zhejiang Cancer Hospital · Updated on 2026-01-16

200

Participants Needed

1

Research Sites

99 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To investigate the real-world efficacy and safety of Sacituzumab govitecan for HER2 negative metastatic breast cancer patients in China.

CONDITIONS

Official Title

To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.

Who Can Participate

Age: 18Years - 75Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female patients aged 18 to 75 years
  • Diagnosis of locally recurrent or metastatic breast cancer suitable for chemotherapy confirmed by tissue analysis
  • HER2-negative breast cancer as defined by 2018 ASCO/CAP guidelines
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2
  • Life expectancy of at least 12 weeks
  • At least one measurable tumor lesion according to RECIST 1.1 criteria
  • Received at least two cycles of Sacituzumab govitecan treatment
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Patients who have not received at least two cycles of Sacituzumab govitecan treatment
  • Diagnosis of other malignant tumors in the past five years, except for cured cervical carcinoma in situ, skin basal cell carcinoma, or skin squamous cell carcinoma
  • Female patients who are pregnant or breastfeeding
  • Women of childbearing age with a positive pregnancy test or unwilling to use effective contraception during the study
  • History of neurological or psychiatric disorders
  • Any other condition deemed unsuitable for participation by the researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Actively Recruiting

Loading map...

Research Team

X

Xiaojia Wang, PhD

CONTACT

H

Huanhuan ZHOU, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China. | DecenTrialz